Loading
SI
Sientra, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Schmidt Andrew C, was filed 25 Aug 2021.
Sientra, Inc.: what insiders have been doing
Sientra, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The past year has been quiet: not a single insider filing for Sientra, Inc. The previous disclosure was published on 14 November 2023.
Our records for Sientra, Inc. go back to 2016, with 3 purchases and 4 sales on the open market in total.
Other companies in the same sector with recent insider buying flagged by our signals: Vivos Inc and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
55
Thresholds
n/a
Buy Volume
€50,274
3 ops. · all time
Sell Volume
€452,392
4 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
Income statement
RevenueUS$78M
Gross profitUS$35.8M46% margin
Net income-US$63.1M-81.0% margin
Last declaration on 14 November 2023
Declarations55 total
3,625 shares@ US$0.710.6% of flowCommon StockSEC:0001213900-23-086856:0
741 shares@ US$0.710.6% of flowCommon StockSEC:0001213900-23-086855:0
2,739 shares@ US$1.755.5% of flowCommon StockSEC:0001213900-23-075850:0
561 shares@ US$3.865.3% of flowCommon StockSEC:0001213900-23-064130:0
12,000 shares0Common StockSEC:0001209191-23-038642:0
15,000 shares0Common StockSEC:0001209191-23-038640:0
12,000 shares0Common StockSEC:0001209191-23-038644:0
12,000 shares0Common StockSEC:0001209191-23-038647:0
12,000 shares0Common StockSEC:0001209191-23-038641:0
2,070 shares@ US$1.383.3% of flowCommon StockSEC:0001209191-23-021111:0
1,725 shares@ US$1.380.5% of flowCommon StockSEC:0001209191-23-021113:0
2,718 shares@ US$1.389.4% of flowCommon StockSEC:0001209191-23-021115:0
1,607 shares@ US$0.230.4% of flowCommon StockSEC:0001209191-23-003368:0
36,500 shares@ US$0.191.6% of flowCommon StockSEC:0001209191-22-056720:0
5,862 shares@ US$0.191.3% of flowCommon StockSEC:0001209191-22-056726:0
6,201 shares@ US$0.9315.3% of flowCommon StockSEC:0001209191-22-044451:0
103,306 shares0Common StockSEC:0001209191-22-036496:0
103,306 shares0Common StockSEC:0001209191-22-036507:0
103,306 shares0Common StockSEC:0001209191-22-036502:0
103,306 shares0Common StockSEC:0001209191-22-036499:0
103,306 shares0Common StockSEC:0001209191-22-036505:0
103,306 shares0Common StockSEC:0001209191-22-036510:0
5,249 shares@ US$1.257.1% of flowCommon StockSEC:0001209191-22-032333:0
4,518 shares@ US$1.518.0% of flowCommon StockSEC:0001209191-22-027326:0
20,000 shares0Common StockSEC:0001209191-22-023456:0
25 of 55 declarations
About Sientra, Inc.
Sientra, Inc. is a United States medical device company focused on surgical aesthetics and breast reconstruction. The business was founded in 2007 and built its brand around a premium portfolio for plastic surgeons, with an emphasis on clinical data, product safety, and technical innovation. Sientra was headquartered in Irvine, California, United States, and was listed on NASDAQ under the ticker SIEN. A key recent development is that the company entered Chapter 11 in February 2024 and subsequently pursued a Section 363 asset sale, which materially changes how investors should view the name, its equity story, and its operating footprint. ([investors.sientra.com](https://investors.sientra.com/overview/?utm_source=openai))
Operationally, Sientra focused on breast implants, tissue expanders, fat grafting solutions, and adjacent products used in plastic surgery. Its portfolio included round and shaped silicone breast implants, the AlloX2 and AlloX2Pro tissue expanders, the Viality fat transfer system, the SimpliDerm human acellular dermal matrix, and BIOCORNEUM scar gel. The company repeatedly highlighted FDA-approved products for the U.S. market and positioned its offering around differentiated clinical performance and surgeon preference. ([investors.sientra.com](https://investors.sientra.com/overview/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Sientra aimed to be a specialized alternative to larger breast implant and surgical-aesthetics players in the United States. Its strategy relied on surgeon relationships, clinical credibility, and an integrated product platform spanning augmentation and reconstruction. Management also used acquisitions and product extensions to broaden the addressable market, including the OPUS implant manufacturing operation, AuraGen fat grafting technology, and the SimpliDerm partnership. These steps were intended to deepen the company’s presence in reconstructive and aesthetic surgery workflows. ([investors.sientra.com](https://investors.sientra.com/overview/?utm_source=openai))
Recent history is dominated by the 2024 restructuring. Sientra filed for Chapter 11 on February 12, 2024, received a Nasdaq delisting notice, and then completed a Section 363 auction process in which Tiger Aesthetics Medical was selected as the winning bidder for the breast reconstruction and augmentation assets, while Nuance Intermediary acquired substantially all assets tied to BIOCORNEUM. For investors, that means Sientra is best understood as a legacy public-company case study in medical-device consolidation and distressed asset monetization rather than a straightforward operating growth story. ([investors.sientra.com](https://investors.sientra.com/news/news-details/2024/Sientra-to-Pursue-Strategic-Sale-of-its-Business-Through-Voluntary-Chapter-11-Process/default.aspx?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
